Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Allergan, Ackman agree special meeting won't trigger poison pill

Published 27/06/2014, 19:09
Allergan, Ackman agree special meeting won't trigger poison pill
AGN_pa
-
BHC
-

(Reuters) - Pershing Square Capital Management, led by activist investor William Ackman, and Allergan Inc (N:AGN) have agreed that calling a special meeting in an effort to elect new board members will not trigger Allergan's so-called "poison pill" measure, settling a lawsuit, the companies said on Friday.

Pershing Square and Valeant Pharmaceuticals International Inc (TO:VRX) (N:VRX) are pursuing Allergan in a $53 billion (31.14 billion pound) hostile takeover bid. Pershing Square has nearly a 10 percent stake in Allergan and if its stake passes 10 percent, Allergan's shareholder rights plan goes into effect and dilutes existing shareholders.

Pershing Square said in a statement that the agreement will allow it to begin soliciting proxies "soon". Valeant issued a statement saying that it was pleased the litigation was resolved and would be "moving forward with our exchange offer."

Pershing Square had filed suit in Delaware earlier this month seeking confirmation that soliciting proxies to call a meeting and replace board members would not trigger the pill. Allergan requires 25 percent of shareholders to call a special meeting.

© Reuters. The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, Quebec

"The rights agreement was drafted in a manner to allow Allergan stockholders to seek to call a special meeting, and the stipulation simply makes it clear how the bylaws and the rights agreement work together," Allergan spokeswoman Bonnie Jacobs said in an e-mailed statement.

Allergan shares were up $1.43, or 0.8 percent, at $171.98 on the New York Stock Exchange. Valeant shares trading on the NYSE were up $1.63, or 1.3 percent, at $128.13.

(Reporting by Caroline Humer and Bill Berkrot; Editing by Marguerita Choy)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.